Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP2 | P12104 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19308493 | 0.87 | KIF11 (0.54) | GABRG2GABRB3GABRA5GABRA3ACLY | |
| SCHEMBL18499494 | 0.87 | KIF11 (0.54) | GABRG2GABRB3GABRA5GABRA3ACLY | |
| SCHEMBL20848692 | 0.87 | ACLY (0.50) | EGLN2CYP19A1GABRG2GABRB3GABRA5 | |
| SCHEMBL27806612 | 0.86 | KIF11 (0.51) | EGLN2PTGS1CYP11B1CYP11B2PDE3B | |
| SCHEMBL16343938 | 0.85 | PTGDR2 (0.49) | PTGDR2CYP19A1GABRG2GABRB3GABRA5 | |
| SCHEMBL29788195 | 0.85 | PTGDR2 (0.49) | PTGDR2CYP19A1GABRG2GABRB3GABRA5 | |
| SCHEMBL34471260 | 0.85 | PTGS1 (0.51) | EGLN2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL20848429 | 0.83 | ACLY (0.50) | EGLN2CYP19A1GABRG2GABRB3GABRA5 | |
| SCHEMBL21742000 | 0.83 | ABCG2 (0.49) | EGLN2CYP19A1GABRG2GABRB3GABRA5 | |
| SCHEMBL20114642 | 0.83 | ABCG2 (0.49) | EGLN2CYP19A1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103517901-A | 1,4-oxazepines as bace1 and/or bace2 inhibitors | HOFFMANN LA ROCHE | 2014-01-15 | — | — | CN | claimed |
| CN-119219454-A | Method for preparing aromatic nitrile compound by photoinitiating nitroarene denitration cyanation | 武汉光化学技术研究院 | 2024-12-31 | — | — | CN | disclosed |
| CN-116199599-B | Method for preparing aryl nitrile compound | 江苏师范大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-112805270-B | 1-Methyl-4- [ (4-phenylphenyl) sulfonylmethyl ] cyclohexanols and 1-methyl-4- [ [4- (2-pyridinyl) phenyl ] sulfonylmethyl ] cyclohexanols compounds and their therapeutic uses | 现代生物科学有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-113766953-B | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses | 现代生物科学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-116199599-A | Method for preparing aryl nitrile compound | 江苏师范大学 | 2023-06-02 | — | — | CN | disclosed |
| EP-3364968-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9850261-B2 | Silicon-based cross coupling agents and methods of their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850261-B2 | Silicon-based cross coupling agents and methods of their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170210766-A1 | SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2170850-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2014653-A1 | Novel dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2009-01-14 | — | — | EP | disclosed |
| EP-2014653-A1 | Novel dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210766-A1 | SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE | RAD51, CA1, DCLRE1A | EGLN2 336/4885PTGDR2 2791/4885CYP19A1 3284/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | EGLN2 1533/4885PTGDR2 3948/4885CYP19A1 2474/4885 |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR2, S1PR5 | EGLN2 2850/4885PTGDR2 263/4885CYP19A1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.